Carcinogenesis, Teratogenesis & Mutagenesis ›› 2022, Vol. 34 ›› Issue (1): 57-61.doi: 10.3969/j.issn.1004-616x.2022.01.011

Previous Articles     Next Articles

Acute toxicity and genotoxicity of antitumor serum thymic factor 9 peptide

YANG Yu1,2, HUANG Yali2,3, LIN Fei2, TANG Long2   

  1. 1. Jiamusi University, College of Basic Medicine, Jiamusi 154007, Heilongjiang;
    2. National Institutes for Food and Drug Control, Beijing 100050;
    3. Research Center of International Inspection, Quarantine Standards and Technical Regulations in General Administration of Customs, Beijing 100013, China
  • Received:2021-05-09 Revised:2021-11-11 Online:2022-01-31 Published:2022-02-15

Abstract: OBJECTIVE: To investigate acute toxicity and genotoxicity of an innovative antitumor drug -serum thymus factor 9 peptide. METHODS: Mice,rats,beagles were given 70.0 mg/kg by one-time injection to test for acute toxicity. Ames test,CHL test and micronucleus test were used to investigate genotoxicity. RESULTS: After treatments,the animals were in good spirits and behaved normally. There were no signs of excitation or inhibition. No acute toxicity was found. Ames test showed no significant increase in the number of mutant colonies at 1-5 000 μg/dish,similar to the solvent control group. CHL test showed no significant increase in chromosome aberration rate at 1 400-5 600 μg/mL (less than 3%),there was no statistical significance compared with the solvent control group (P>0.05). The micronucleus cell rates in the 17.5-70.0 mg/kg group were all less than 2.0‰,and there was no statistical significance compared with the solvent control group (1.2‰) (P>0.05). CONCLUSION: The maximum tolerated dose of serum thymic factor 9 peptide was greater than 70.0 mg/kg,which was 930 times of the recommended dosage for clinical patients. Acute toxicity and genotoxicity were not observed in the dose ranges for this investigation.

Key words: serum thymic factor 9 peptide, rats, mice, Beagles, acute toxicity, genotoxicity

CLC Number: